Sanofi Price & Performance (SNY)

Sanofi reported a nearly 10% rise in first-quarter sales, driven by robust demand for new medicines and vaccines. The company confirmed its 2025 outlook for mid- to high-single-digit sales growth and a double-digit rebound in earnings. Recent regulatory approvals and pipeline advances underpin confidence in future performance.123

Sanofi and Sobi have renewed their collaboration with the World Federation of Hemophilia, continuing to provide critical access to hemophilia treatments in underserved regions. The extended partnership aims to deliver long-term humanitarian support, reflecting Sanofi’s ongoing commitment to global health initiatives and patient access.456

Innate Pharma announced a €15 million investment from Sanofi, strengthening their strategic relationship. The funding will support Innate Pharma’s research and development efforts, particularly in immuno-oncology, and highlights Sanofi’s ongoing interest in innovative biotech collaborations to expand its early-stage pipeline.78